Terumo Launches SurTract(TM) Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology
MWN-AI** Summary
Terumo Medical Corporation has announced the launch of its innovative SurTract™ Safety Syringe in the United States, aimed at enhancing safety and efficiency in medical injections. This syringe incorporates SafeR® passive safety technology developed by Roncadelle Operations, providing a fully automatic retraction mechanism that accommodates immediate withdrawal of the needle into the plunger after use. This feature significantly mitigates the risk of needle-stick injuries, which pose a hazard to healthcare providers, while ensuring a smoother and more comfortable experience for patients.
Available for distribution in hospitals, clinics, and emergency care settings starting in the first quarter of 2026, the SurTract Syringe is designed with several advantages. It allows for customizable needle selections, accommodating varied clinical needs for optimal patient care. Additionally, the inclusion of a blunt needle prevents dullness and enables needle changes during procedures. The syringe is engineered to reduce medical waste by eliminating the requirement for an external safety sheath, and it limits medication waste thanks to its low dead space design.
Key stakeholders, including Terumo’s Vice President Bob Klock and Roncadelle’s Chief Business Development Officer Dr. Fred Metzmann, emphasize that the SurTract Syringe merges Terumo’s clinical expertise with Roncadelle’s validated technology, thus creating a reliable solution for safer injections. Terumo, a global leader in medical innovation since 1921, continues to fulfill its mission of contributing to society through healthcare, while Roncadelle Operations specializes in developing advanced medical devices and ensuring quality through ISO compliance and FDA clearances.
This collaboration between Terumo and Roncadelle represents a substantial advancement in injection safety, providing healthcare professionals with enhanced tools to deliver improved patient care.
MWN-AI** Analysis
Terumo Medical Corporation's recent launch of the SurTract™ safety syringe in the United States marks a significant advancement in medical device innovation, particularly in the safety and efficacy of injection practices. Powered by Roncadelle Operations' SafeR® passive safety technology, this product not only enhances safety for healthcare professionals by minimizing the risk of needle-stick injuries but also improves patient comfort during administration.
From a market perspective, the introduction of the SurTract safety syringe aligns with the growing demand for safer medical devices in the healthcare sector. With an increasing focus on patient safety regulations and cost-effective healthcare solutions, Terumo's innovative approach reinforces its competitive positioning within the medical device industry. The customizable needle selections and reduced medical waste directly address market demands for improved efficiency and sustainable practices, making the SurTract syringe an attractive option for hospitals and clinics seeking to enhance their operational protocols.
Investors should note that Terumo's commitment to innovation could translate into a significant revenue stream, particularly as healthcare facilities increasingly prioritize safety measures. The synergy between Terumo and Roncadelle further enhances their ability to capitalize on emerging trends within healthcare technology, potentially increasing their market share.
Moreover, the expansion into the U.S. market presents an opportunity for Terumo to tap into the largest healthcare sector globally, promising substantial growth prospects. As the company rolls out the SurTract syringe beginning Q1 2026, monitoring adoption rates and physician feedback will be critical to gauge its success.
In conclusion, Terumo's introduction of the SurTract safety syringe, with its advanced safety features and sustainability benefits, represents both a timely response to industry needs and a promising growth opportunity for the company and its investors. Careful observation of market uptake will be essential moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- New, retractable safety hypodermic line offers enhanced safety, reliability and ease of use while minimizing patient discomfort* -
SOMERSET, N.J., Jan. 6, 2026 /PRNewswire/ -- Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ Safety Syringe, powered by SafeR® passive safety technology developed by Roncadelle Operations S.r.l. The SurTract Syringe will be distributed across hospitals, clinics, and emergency-care settings beginning in the first quarter of 2026.
SafeR technology provides the SurTract Syringe with a fully passive, automatic retraction mechanism that withdraws the needle into the plunger immediately after use – helping reduce the risk of needle-stick injuries for physicians, and providing patients with a smooth and comfortable injection due to less plunger pressure*. The syringe system also preserves standard clinical technique while offering enhanced safety, reliability and ease of use.
Other benefits include:
- A customizable needle selection designed for use exclusively with SurTract Syringes, allowing physicians the opportunity to create the combination they need for optimal patient care.
- A blunt needle, preventing dullness and allowing a change of needle for drawing up aspiration.
- Less medical waste due to a lack of an external plastic safety sheath.
- Reduction in medication waste due to the low dead space syringe*.
"The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections," said Bob Klock, Vice President, Terumo Medical Corporation. "It gives healthcare providers more – and better – treatment options for their patients, which is our ultimate goal."
"Terumo has significantly advanced injection safety with the integration of our SafeR technology," said Dr. Fred Metzmann, Chief Business Development Officer at Roncadelle Operations. "Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals."
About Terumo
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. More information can be found at www.terumo.com.
About Roncadelle Operations
Roncadelle Operations S.r.l., headquartered in Brescia, Italy, develops and manufactures advanced medical devices, components and pharmaceutical packaging under its brand vision: MedTech Solutions – Engineered to Protect. Its proprietary SafeR® product line includes passive safety syringes and passive needle-guard systems for pre-filled syringes – designed for Safe Injection and Smart Protection in clinical environments. All products comply with ISO 11040-7 and ISO 23908 and are FDA 510(k)-cleared. As a trusted CDMO partner to global pharmaceutical and medical-device companies, Roncadelle integrates precision molding, automated assembly and packaging under cleanroom conditions to ensure consistent quality, full traceability and scalable manufacturing capacity – Performance You Can Trust. More information can be found at: www.roncadelle-operations.com.
*Data on file
SOURCE Terumo Medical Corporation
FAQ**
How does the SurTract™ Safety Syringe, powered by Roncadelle Operations' SafeR® technology, position Terumo Corporation ADR TRUMY within the highly competitive medical device market?
What specific clinical advantages does the SurTract™ Safety Syringe offer healthcare professionals that could influence demand for Terumo Corporation ADR TRUMY products?
What is Terumo Corporation ADR TRUMY's projected market share in the safety syringe segment following the US launch of the SurTract™ Safety Syringe in 2026?
How will Terumo Corporation ADR TRUMY leverage the innovative features of the SurTract™ Safety Syringe to differentiate itself from competitors in the healthcare sector?
**MWN-AI FAQ is based on asking OpenAI questions about Terumo Corporation ADR (OTC: TRUMY).
NASDAQ: TRUMY
TRUMY Trading
0.98% G/L:
$12.91 Last:
34,185 Volume:
$12.51 Open:
